Polygenic Risk Score Outperforms PSA and MRI in Detecting Clinically Significant Prostate Cancer: NEJM Dr Riya Dave28 July 2025 8:15 PM ISTResearchers have found in a new BARCODE1 study that a polygenic risk score identified a higher proportion of clinically significant prostate cancer...
Bayer Nubeqa gets EU nod in third indication for advanced prostate cancer Ruchika Sharma22 July 2025 10:30 AM ISTBerlin: Bayer has received marketing authorization from the European Commission in the European Union (EU) for Nubeqa (darolutamide), an oral...
Biocon Biologics gets marketing nods in UK for Vevzuo, Evfraxy Ruchika Sharma7 July 2025 11:12 AM ISTBengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd., has received marketing...
JnJ seeks indication extension of Akeega from EMA for adults with metastatic hormone-sensitive prostate cancer, HRR gene alterations Ruchika Sharma6 July 2025 12:30 PM ISTBelgium: Janssen-Cilag International NV, a Johnson & Johnson company, has announced the submission of an extension of indication application...
Biocon Biologics gets EU nod for bone disease treatments, including Osteoporosis, giant cell tumour of bone Ruchika Sharma3 July 2025 11:29 AM ISTBengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd., has announced that the...
Botox mitigates debilitating dry mouth in prostate cancer patients receiving radiopharmaceutical therapy: Study Dr. Kamal Kant Kohli29 Jun 2025 8:15 PM ISTA dual-protective approach using botulinum toxin (Botox) alongside an anti-nausea patch significantly reduces salivary gland toxicity in patients with...
EMA Committee recommends marketing nod for Bayer advanced prostate cancer drug darolutamide Ruchika Sharma22 Jun 2025 1:00 PM ISTBerlin: Bayer has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has...
Phase 3 trial initiated for Ifinatamab Deruxtecan in Pretreated Metastatic Castration-Resistant Prostate Cancer: Merck, Daiichi Sankyo Ruchika Sharma19 Jun 2025 10:00 AM ISTBasking Ridge: Merck and Daiichi Sankyo have announced that the first patient has been dosed in the IDeate-Prostate01 phase 3 trial evaluating...
UC Davis clinical trial shows biomarkers hold clue in treating aggressive prostate cancer Dr. Kamal Kant Kohli17 Jun 2025 8:30 PM ISTMany men with aggressive prostate cancer can experience a high rate of recurrence despite treatment. A new Phase 2 clinical trial at UC Davis...
Bayer Prostate Cancer Drug Nubeqa gains third regulatory win from USFDA Ruchika Sharma4 Jun 2025 2:59 PM ISTBerlin: Bayer has received approval from the U.S. Food and Drug Administration (FDA) for its oral androgen receptor inhibitor (ARi) Nubeqa...
Two-week radiotherapy as safe and effective as eight-week course for prostate cancer: phase III trial Dr. Kamal Kant Kohli18 May 2025 9:00 PM ISTProstate cancer is the most commonly diagnosed cancer in men worldwide, accounting for more than 1.4 million new cases each year . For many patients,...
More men with prostate cancer are avoiding unnecessary surgery, reveals JAMA study Dr. Kamal Kant Kohli14 May 2025 9:00 PM ISTProstate cancer is a leading cause of cancer-related death among men in the United States. Despite this, widespread adoption of prostate cancer...
